TriLink BioTechnologies Announces Agreement with American Cleanroom Systems to build cGMP Facility
The pharmaceutical cGMP production facility will contain nine labs and be equipped to manufacture and process mRNA, long RNA, aptamers, oligonucleotides, small molecules and nucleoside triphosphates. The project is scheduled to be complete in the first quarter of next year.
"Building a pharmaceutical cGMP production facility is the next logical step in expanding our quality system. Soon we will be able to support our customers at every stage from research to clinical trials and commercialization," said TriLink CEO, Richard Hogrefe, Ph.D. "ACS offered the quality and experience we were seeking and we're confident they are the right contractor to help us meet these goals."